CD274 and triple-negative breast carcinoma: In addition, patients with metastatic triple-negative breast cancer with a higher PD-L1 expression showed a better clinical response than patients with a lower PD-L1 expression after treatment with atezolizumab in combination with nab-paclitaxel (134, 135).